Overview

An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies

Status:
RECRUITING
Trial end date:
2026-12-30
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, phase I clinical study of YY201 in the patients with relapsed/refractory lymphomas and relapsed/refractory large granular lymphocytic leukemia who failed or cannot tolerate standard treatment.
Phase:
PHASE1
Details
Lead Sponsor:
Shanghai Yuyao Biotech Co., Ltd.